Livongo Health (NASDAQ:LVGO) Receives Consensus Rating of “Buy” from Brokerages

Livongo Health (NASDAQ:LVGO) has been assigned an average rating of “Buy” from the ten ratings firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $44.20.

Several equities analysts have weighed in on LVGO shares. Leerink Swann started coverage on shares of Livongo Health in a report on Monday, August 19th. They set an “outperform” rating and a $50.00 price target on the stock. KeyCorp began coverage on shares of Livongo Health in a research report on Monday, August 19th. They set an “overweight” rating and a $46.00 price objective on the stock. Needham & Company LLC began coverage on shares of Livongo Health in a research report on Monday, August 19th. They set a “buy” rating and a $42.00 price objective on the stock. Chardan Capital began coverage on shares of Livongo Health in a research report on Friday, August 16th. They set a “neutral” rating and a $40.00 price objective on the stock. Finally, JPMorgan Chase & Co. began coverage on shares of Livongo Health in a research report on Monday, August 19th. They set an “overweight” rating and a $43.00 price objective on the stock.

NASDAQ:LVGO traded down $0.09 during trading hours on Friday, hitting $22.48. 9,288 shares of the stock traded hands, compared to its average volume of 1,045,553. Livongo Health has a 1 year low of $22.30 and a 1 year high of $45.68. The firm has a 50 day moving average of $32.16.

Livongo Health (NASDAQ:LVGO) last issued its quarterly earnings results on Thursday, September 5th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.29). The business had revenue of $40.90 million for the quarter, compared to analyst estimates of $39.74 million. The company’s quarterly revenue was up 155.6% on a year-over-year basis. As a group, research analysts expect that Livongo Health will post -1.29 EPS for the current year.

In other Livongo Health news, Director Hemant Taneja purchased 2,678,571 shares of Livongo Health stock in a transaction that occurred on Monday, July 29th. The shares were bought at an average price of $28.00 per share, for a total transaction of $74,999,988.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Ab (Publ) Kinnevik purchased 3,141,795 shares of Livongo Health stock in a transaction that occurred on Monday, July 29th. The stock was acquired at an average price of $28.00 per share, for a total transaction of $87,970,260.00. The disclosure for this purchase can be found here. Insiders purchased 5,826,366 shares of company stock worth $162,980,808 in the last 90 days.

Livongo Health Company Profile

Livongo Health, Inc provides an integrated suite of solutions for the healthcare industry in North America. It solutions promote health behavior change based on real-time data capture supported by intuitive devices and insights driven by data science. The company offers a platform that provides cellular-connected devices, supplies, informed coaching, data science-enabled insights, and facilitates access to medications.

See Also: Exchange-Traded Funds (ETFs)

Analyst Recommendations for Livongo Health (NASDAQ:LVGO)

Receive News & Ratings for Livongo Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Livongo Health and related companies with MarketBeat.com's FREE daily email newsletter.